Signaling Update contents for 30 January 2009

	Signaling Update — 30 January 2009 Signaling Update is a one-stop online resource designed to keep you in touch with the latest and most exciting research in cell signaling. New content is uploaded every Friday.
	New in Signaling Update this week:
	featured article  Melanoma: A G protein mutation gets under the skin Researchers have found a point mutation in the heterotrimeric G protein α subunit GNAQ that activates the MAPK pathway in a subset of melanomas. Original paper: Nature 457, 599-602 (2009) previous featured articles selected updates  Inflammation: Recruitment freeze The glycoprotein DEL1 (developmental endothelial locus 1) inhibits leukocyte recruitment by interfering with integrin-dependent neutrophil adhesion to ICAM1 in target tissues. Original research paper: Science 322, 1101-1104 (2008) Genomics: Distinguishing drivers from passengers An RNAi-based screening approach has been used in a mosaic mouse model of hepatocellular carcinoma to identify novel potential tumor suppressor genes. Original research paper: Cell 135, 852-864 (2008) Cytoskeleton: Invading forces A splice variant of the actin-associated protein MENA can promote invasion and metastasis of breast cancer cells by facilitating elongation of cofilin-generated barbed ends, leading to increased actin polymerization and lamellipodia extension. Original research paper: Dev. Cell 15, 813-828 (2008) more updates research library  The Research Library brings together all recent signaling-related research published in the Nature Publishing Group journals. Divided up into subject categories or by date, you can be guaranteed to find what you are looking for. Here is a selection of the newest and hottest research published this week. An inducible autoregulatory loop between HIPK2 and Siah2 at the apex of the hypoxic response Nature Cell Biology 11, 85-91 (2009) Subscribe to this journal Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa Nature Neuroscience 12, 44-52 (2009) Subscribe to this journal TGFβ-stimulated Smad1/5 phosphorylation requires the ALK5 L45 loop and mediates the pro-migratory TGFβ switch The EMBO Journal 28, 88-98 (2009) Subscribe to this journal signaling news  Nature News: China targets top talent from overseas China has announced a nationwide plan that promises top salaries and attractive funding to elite researchers who are working overseas and willing to return to the country. It offers a relocation package of 1 million renminbi (US$146,000) per person, with salaries and research funding left to universities and institutes to sort out. Previous approaches have lured more than 4,000 researchers, mostly at postdoctoral or assistant-professor levels, back to the country in the past fifteen years. more news gateway updates  The Functional Glycomics Gateway - January Update The Functional Glycomics Gateway is a comprehensive FREE online resource to keep you abreast of the latest findings in the field. This month's update features: Bacterial infection: Receptor glycans form a crucial interface and Tissue development: Cleaving an acidic sugar promotes differentiation. Sign up to receive the monthly table of contents e-alert for the Functional Glycomics Update. job of the week  from naturejobs the scientific careers resource Faculty Positions in Cell Signaling, Physiology and Pharmacology Employer: University of Texas Medical School at Houston Location: Houston, Texas, USA The Department of Integrative Biology and Pharmacology in the University of Texas Medical School at Houston has multiple tenure-track faculty openings for investigators studying the biology, physiology or pharmacology of cell signaling or cell-cell interactions. Applicants with a strong interest in cardiovascular biology and physiology, or cell migration and metastasis using animal model systems are especially encouraged to apply. more jobs To advertise a job in this spot, please contact Naturejobs.
	Genentech is proud to be a corporate sponsor of the UCSD-Nature Signaling Gateway. Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes biotherapeutics for significant unmet medical needs. Fifteen of the currently approved biotechnology products stem from or are based on Genentech science. Genentech manufactures and commercializes ten biotechnology products directly in the United States. The company has headquarters in South San Francisco, California, and is traded on the New York Stock Exchange under the symbol DNA. www.biooncology.com As a registered user of the Nature Publishing Group web sites, you were selected to receive this message in the genuine belief that it would be of interest to you. If you no longer wish to receive news and announcements from Nature Publishing Group or wish to unsubscribe from the Signaling Update email alert please update your online Nature.com account details here. For further technical assistance or any other enquiries, please click here. Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne - San Diego - San Francisco - Washington - New York - Boston © 2009 Nature Publishing Group Privacy Policy